Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1

EF 2019-20

Résumé
"Myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy in Canada and worldwide, is a hereditary neuromuscular disorder that results in skeletal muscle weakness, wasting and myotonia. Due to its progressive nature, individuals with DM1 may experience difficulties in carrying out activities of daily living, and in severe cases, lose the ability to walk or breathe independently. In addition to skeletal muscle dysfunction, the symptoms of DM1 are multisystemic and can include cataracts, insulin resistance, heart problems, gastrointestinal issues, as well as cognitive impairments. To date, there is no cure for this debilitating disease. Recent work from our lab has revealed that AMP-activated protein kinase (AMPK) signaling, a key cellular pathway that maintains skeletal muscle mass and function, is repressed in a mouse model of DM1. Stimulation of this pathway using drugs or exercise, has beneficial effects in the skeletal muscles of DM1 mice. However, the methods of AMPK activation used to date are also known to have additional effects on other cellular pathways, thereby confounding the therapeutic role of AMPK in these studies. Here, I propose to treat DM1 mice with novel AMPK-activating compounds designed to specifically target this pathway. The functional, cellular, and molecular characteristics of skeletal muscle tissue will be analyzed in order to evaluate improvements in the DM1 pathology. In addition, I will initiate a combinatorial approach with AMPK-activating drugs and daily exercise to determine if these improvements are further enhanced in an additive manner. These findings will enable us to better understand the therapeutic role of AMPK in DM1 and contribute to the development of novel treatment strategies for DM1 patients."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428988
Name
Misquitta Naomi S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Amp-Activated Protein Kinase; Combinatorial Therapeutics; Exercise Training; Muscular Dystrophy; Myotonic Dystrophy Type 1; Pharmacological Treatment Strategies; Skeletal Muscle
Abstract
"Myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy in Canada and worldwide, is a hereditary neuromuscular disorder that results in skeletal muscle weakness, wasting and myotonia. Due to its progressive nature, individuals with DM1 may experience difficulties in carrying out activities of daily living, and in severe cases, lose the ability to walk or breathe independently. In addition to skeletal muscle dysfunction, the symptoms of DM1 are multisystemic and can include cataracts, insulin resistance, heart problems, gastrointestinal issues, as well as cognitive impairments. To date, there is no cure for this debilitating disease. Recent work from our lab has revealed that AMP-activated protein kinase (AMPK) signaling, a key cellular pathway that maintains skeletal muscle mass and function, is repressed in a mouse model of DM1. Stimulation of this pathway using drugs or exercise, has beneficial effects in the skeletal muscles of DM1 mice. However, the methods of AMPK activation used to date are also known to have additional effects on other cellular pathways, thereby confounding the therapeutic role of AMPK in these studies. Here, I propose to treat DM1 mice with novel AMPK-activating compounds designed to specifically target this pathway. The functional, cellular, and molecular characteristics of skeletal muscle tissue will be analyzed in order to evaluate improvements in the DM1 pathology. In addition, I will initiate a combinatorial approach with AMPK-activating drugs and daily exercise to determine if these improvements are further enhanced in an additive manner. These findings will enable us to better understand the therapeutic role of AMPK in DM1 and contribute to the development of novel treatment strategies for DM1 patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Misquitta, Naomi S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~